MEPs Tomislav Sokol and Ondřej Knotek clashed with Commissioner Olivér Várhelyi over the Urban Wastewater Treatment Directive, expressing concern that Extended Producer Responsibility (EPR) obligations could impose disproportionate burdens on generic drug manufacturers, potentially weakening Europe's generics sector. Both MEPs called for a one-year pause to reassess the directive's impact. Meanwhile, Várhelyi acknowledged related risks but defended the Commission's position, suggesting a temporary pause might be prudent.
Another flashpoint involved cuts to operating grants for health NGOs. Vytenis Andriukaitis and Christophe Clergeau criticized the Commission's budgetary decisions, warning that such financial reductions could undermine NGOs' capacity for cross-border health initiatives like HIV prevention. Várhelyi countered, arguing performance-based financing could improve outcomes and might increase total funding despite the €9.3 million cuts required by the current Multiannual Financial Framework (MFF) constraints.
This intense exchange unfolded during the European Parliament’s Committee on Public Health (SANT) meeting on 27 January 2026, featuring Commissioner Várhelyi. The session covered a spectrum of public health policies including the Biotech Act, Safe Hearts Plan for cardiovascular prevention, medical device regulation, health NGO funding, and the Urban Wastewater Treatment Directive.
Commissioner Várhelyi provided concrete timelines and financial targets, such as mobilizing €10 billion in biotech investments by 2027 through the Biotech EU initiative partnered with the European Investment Bank (EIB), and a 25% reduction target in premature cardiovascular deaths by 2035 under the Safe Hearts Plan. However, some proposals—like the temporary pause on the Urban Wastewater Directive or the potential restructuring of NGO funding—were addressed more cautiously, with Várhelyi balancing budget realities and performance expectations rather than concrete reversals.
MEPs like Knotek and Voiculescu sought greater strategic autonomy in biotech funding and voiced the need for nuanced public health approaches, illustrating a cleavage between enhancing EU-level financial instruments versus pragmatic budget constraints. On NGO funding, parliamentarians’ call for preserving operational grants contrasted with the Commission's pivot toward outcome-based funding models.
Other topics revealed divides on regulatory burden versus business competitiveness, notably around medical device simplification championed by Várhelyi, who promised streamlined 105-day certification and AI integration support against concerns from MEPs about safety and transparency.
The debate underscored tensions between increasing EU regulatory and financial powers to achieve strategic health autonomy and pressures to contain costs amid competing priorities. Stakeholders directly impacted include generic pharmaceutical producers facing higher compliance costs under the wastewater directive, health NGOs confronting uncertain funding, and biotech firms targeted by new capital mobilization efforts.
Looking forward, the European Parliament and Commission are likely to continue negotiating refined legislative texts that balance innovation and prevention goals with industry competitiveness and civil society engagement, particularly in health NGO funding and environmental regulations affecting pharmaceutical production. The Commission’s emphasis on technology-driven, prevention-focused healthcare and targeted investment signals a strategic shift that will shape EU health policy across coming budgets.